2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 343-345
Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Immunotherapy, Biological Processes, Hematopoiesis, Immune Mechanism, Diseases, Immunology, GVHD, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Animal Model
PAPER

699 Characterizing tissue-resident donor CD4⁺ T cell states, clonal architecture, and in vivo persistence of TCF-1⁺ progenitors in graft-versus-host disease

Tsuyoshi Fujita, MD, PhD, Sarah Rosenberger, MS2, Mathavan Murali, MS3, Kevin Quann, MD, PhD4, Warren Shlomchik, MD5, Faruk Sacirbegovic, PhD6
1 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
4 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
6 University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Graft-versus-host disease (GVHD) remains a leading cause of morbidity and mortality after allogeneic hematopoietic cell transplantation. Using parabiosis in 3 GVHD models and T cell clone analysis in a CD4? TCR-transgenic (Tg) model, we previously demonstrated that GVHD is dominantly maintained locally within tissues, relatively independent of newly recruited blood-derived T cells. Adoptive transfer of T cell subsets from mice with established GVHD into newly transplanted mice suggested that intratissue Tcf7-expressing (TCF-1?) cells could be a key tissue-resident progenitor (Tpro) population that generates mature TCF-1? effectors (Teff). However, definitively proving this Tpro to Teff relationship requires approaches other than adoptive T cell transfer. To do so we applied single-cell RNA sequencing (scRNA-seq) with TCR capture and fate-mapping of Tcf7-expressing cells after GVHD establishment in the polyclonal, MHC-matched CD4+ T cell B6.C to BALB/c (H-2d) GVHD model.

Irradiated CD45.2 BALB/c mice were reconstituted with CD45.2 B6.C bone marrow and purified CD45.1 CD4 cells. Four weeks after transplant, we profiled donor-derived CD45.1?, tissue-resident (intravascular-excluded) CD4? T cells from the spleen, skin, small intestine, and colon of 3 recipients, resolving the small intestine and colon into lamina propria (LP) and intraepithelial (IEL) compartments by Itgae expression. CD4? T cell states were defined within each compartment, and clones were tracked by their paired TCRa/b sequences within each recipient, restricting comparisons across recipients to shared clones which must have been represented multiple times in the donor T cell inoculum. Across these 6 compartments we observed a reproducible set of CD4? transcriptional states, including a Tcf7? progenitor compartment that resolved into populations with a Th1 bias (Ifngr1+Tbx21?) or a Tfh bias (Il4?Il21?) which were distinguished from naïve cells by low Sell. We also observed Treg (Foxp3?Ikzf2?) and Th17 (Rorc?Il17a?) programs with no clonal overlap between Treg and other subsets. Treg and quiescent/resting states recurred across all 6 compartments, whereas Th17 was restricted to the skin and gut, and the progenitor and cytotoxic programs to the spleen and gut. Notably, the skin effector compartment was predominantly non-cytotoxic. As in the TCR-Tg model, clonal expansion (oligoclonality) was greatest among gut intraepithelial cells. Within individual mice, many clones were shared across tissues, consistent with widespread early seeding; yet clonal compositions diverged across compartments, consistent with local maintenance. Clonal siblings tended to occupy the same transcriptional state more often than expected under label permutation, consistent with TCR:antigen combinations shaping differentiation. Among clones shared across recipients, fate was concordant while clone size was not, indicating an association between the TCR and cell state that was independent of expansion magnitude, possibly due to stochasticity. Transcriptional pseudotime rooted on tissue progenitors supported a Tpro to Teff differentiation axis, with stemness genes declining and cytotoxic genes increasing along pseudotime. To more directly test whether Tcf7-expressing cells differentiate into Tcf7-negative Teff, we performed fate mapping in the same B6.C?BALB/c model using CD4 cells from Tcf7-ERT2cre-GFP BAC transgenic mice crossed to ROSA26 lox-stop-lox hNGFR mice. In these cells, GFP reports ongoing Tcf7 expression, whereas tamoxifen pulsing permanently marks Tcf7-expressing cells and their progeny with hNGFR, independent of their subsequent Tcf7 status. Mice were treated with tamoxifen (days 21 to 25), and tissues were analyzed on days 26, 40, and 60. Labeling was selective, with hNGFR? cells almost uniformly GFP? (TCF-1+) at day 26. Over time, the fraction of hNGFR+ cells that were GFP- (TCF-1-) progressively increased, consistent with differentiation of Tpro into Teff. Notably, the hNGFR?GFP? Tpro pool was maintained in all tissues through day 60, suggesting Tpro self-renewal.

Taken together, these  data extend our resident-Tpro model from a TCR-transgenic system to a more physiological, polyclonal model, indicating that resident TCF-1? CD4? progenitors are maintained long-term across GVHD target tissues and give rise to differentiated progeny in vivo.

Tsuyoshi Fujita, MD, PhD: No relevant conflicts of interest to declare.